Docoh
Loading...

ONCY Oncolytics Biotech

Press releases

From Benzinga Pro
Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium
19 Nov 21
Small Cap, Press Releases
IRENE study is evaluating pelareorep-anti-PD-1 combination treatment in metastatic TNBC SAN DIEGO and CALGARY, AB, Nov. 19, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that the
Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results
5 Nov 21
Earnings, Small Cap, Press Releases
Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker Advanced collaboration with Roche and AIO by initiating dosing in phase 1/2 GOBLET trial in
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
3 Nov 21
Small Cap, Opinion, Press Releases
PALM BEACH, Fla., Nov. 3, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast, lung,
Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers
3 Nov 21
Press Releases
Multi-center trial is being conducted in collaboration with Roche and AIO Trial is designed to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple gastrointestinal cancer
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
19 Oct 21
Press Releases
SAN DIEGO and CALGARY, AB, Oct. 19, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021, at 8:00 a.m. ET
Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming Peers
14 Oct 21
Opinion, Press Releases
VANCOUVER, BC, Oct. 14, 2021 /PRNewswire/ -- USA News Group - Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and the S&P 500 and Nasdaq doing even better with
Accelerating R&D Activities in Breast Cancer Therapy Market Fueling Optimism for Development of Advanced Treatments
14 Oct 21
Small Cap, Opinion, Press Releases
PALM BEACH, Fla., Oct. 14, 2021 /PRNewswire/ -- The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend for the next several years. The breast cancer
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
14 Oct 21
Small Cap, Press Releases
Trial is designed to advance pelareorep's clinical development in China, the world's second-largest pharmaceutical market SAN DIEGO and CALGARY, AB, Oct. 14, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc.
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
20 Sep 21
Small Cap, Opinion, Press Releases
VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ -- USA News Group - Oncology data leader COTA recently released a recent survey where half of the respondents pointed to "Operation Warp Speed" as evidence that cancer
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
20 Sep 21
Small Cap, Opinion, Press Releases
PALM BEACH, Fla., Sept. 20, 2021 /PRNewswire/ -- Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more
Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy
20 Sep 21
Small Cap, Press Releases
SAN DIEGO and CALGARY, AB, Sept. 20, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep